Independent reproducibility and evidence assessment
Our due diligence services include independent reproducibility studies and scalability assessments, drawing on our molecular biology, custom assay, cell analysis and bioinformatics capabilities. A project may focus on reproducing a central result, checking it with an orthogonal readout, examining a workflow’s performance or assessing existing data. We define the question and the evidence required before scoping the work.
What your project can include
The agreed package can include experimental protocols, controls and QC, data analysis, a method report and interpretation of the findings. Reporting should distinguish what was reproduced, what remains uncertain and which follow-up experiments would inform the next decision. We assess wet-lab and computational findings in the context of the specific biological claim, recognizing that they provide different kinds of evidence.
How to get started
Tell us which claim or asset you want to assess and what decision you need to make. We can discuss the available evidence and materials together. If needed, ask for an NDA before sharing confidential details.
Common questions
Who is this service for?
This service supports biotech and pharma teams evaluating their own programs, as well as investors and partners who need independent biological evidence. We tailor the scope to the question, available materials and decision criteria.
How does this differ from a go/no-go experiment?
Due diligence can assess a broader body of evidence, including reproducibility and scalability. A go/no-go experiment is a focused study built around a specific decision. The two can be combined when a wider review identifies a critical experiment.